Search clinical trials for: Comparator: MK-0773

Total 3766 results

Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)

Sarcopenia
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Terminated

An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

Lung Diseases | Pulmonary Disease, Chronic Obstructive
University of California, Los Angeles
Massachusetts General Hospital; Washington University School of Medicine; University... and other collaborators

Completed

Treatment Study for Cognitive Deficits in Schizophrenia (TURNS)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

Plaque Psoriasis
Merck Sharp & Dohme LLC

Terminated

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Type 2 Diabetes
Clinical Nutrition Research Center, Illinois Institute...

Completed

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance (GSE3)

Impaired Glucose Tolerance

United States
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Completed

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

Type 2 Diabetes
Merck Sharp & Dohme LLC
FoxHollow Technologies

Terminated

A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Peripheral Vascular Diseases
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Schizophrenia

United States
Merck Sharp & Dohme LLC

Terminated

Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)

Hypertension | Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

Psoriasis | Plaque Psoriasis

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)

Advanced Cancer
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)

Hepatitis C
Genentech, Inc.

Completed

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

Healthy Volunteers
Organon and Co

Completed

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

Hypercholesterolemia
Genentech, Inc.

Completed

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

Healthy Volunteer

United States
Kissei Pharmaceutical Co., Ltd.

Completed

A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Kissei Pharmaceutical Co., Ltd.

Completed

An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Daiichi Sankyo, Inc.

Completed

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

Multiple Sclerosis

United States
Merck Sharp & Dohme LLC

Terminated

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Diabetes Mellitus, Type 2
Evolva SA

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

Type 2 Diabetes

Germany
Organon and Co

Completed

A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Genentech, Inc.

Completed

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

Healthy Volunteers
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Acute Bacterial Skin and Skin Structure Infections

United States, Brazil, Bulgaria, Georgia, Germany, Guatemala, Latvia, Lithuania, Mexico, Poland, Russian Federation, South Africa, Turkey, Ukraine
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Merck Sharp & Dohme LLC

Completed

MK-0524B Lipid Study (MK-0524B-063)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Eisai Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Alzheimer's Disease

United States
Kissei Pharmaceutical Co., Ltd.

Completed

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Spinocerebellar Degeneration

Japan
Genentech, Inc.

Completed

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Neoplasms

United States, Spain
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Breast Cancer
Merck Sharp & Dohme LLC

Terminated

The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

Middle Cerebral Artery Stroke
TiumBio Co., Ltd.

Recruiting

TUC3PII-01_TU2670 Phase IIa Clinical Study

Endometriosis

Czechia, Italy, Russian Federation, Poland, Ukraine
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Non-Small Cell Lung Cancer
Cognition Therapeutics

Recruiting

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Age-Related Macular Degeneration

United States

3

Subscribe